Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare Sonrotoclax (BGB-11417) più Zanubrutinib (BGB-3111) rispetto a Venetoclax più Acalabrutinib in adulti con leucemia linfatica cronica precedentemente non trattata

24 settembre 2026 aggiornato da: BeOne Medicines

Uno studio di fase 3, in aperto, randomizzato su sonrotoclax (BGB-11417) più zanubrutinib (BGB-3111) rispetto a venetoclax più acalabrutinib in pazienti con leucemia linfatica cronica non precedentemente trattata

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

500

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New South Wales
      • Blacktown, New South Wales, Australia, NSW 2148
        • Reclutamento
        • Blacktown Cancer and Haematology Centre
      • Concord, New South Wales, Australia, NSW 2139
        • Reclutamento
        • Concord Repatriation General Hospital
      • St Leonards, New South Wales, Australia, NSW 2065
        • Reclutamento
        • Genesiscare North Shore
    • Queensland
      • Woolloongabba, Queensland, Australia, QLD 4102
        • Reclutamento
        • Princess Alexandra Hospital
    • Victoria
      • Clayton, Victoria, Australia, VIC 3168
        • Reclutamento
        • Monash Health
      • Heidelberg, Victoria, Australia, VIC 3084
        • Reclutamento
        • Austin Health
      • Malvern, Victoria, Australia, VIC 3144
        • Reclutamento
        • Cabrini Hospital Malvern
      • Melbourne, Victoria, Australia, VIC 3004
        • Reclutamento
        • The Alfred Hospital
      • Brasília, Brasile, 70390140
        • Reclutamento
        • Instituto Dor de Pesquisa E Ensino Distrito Federal
      • Porto Alegre, Brasile, 90110-270
        • Reclutamento
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Salvador, Brasile, 41950-640
        • Reclutamento
        • Ensino E Terapia de Inovacao Clinica Amo Etica
      • São Paulo, Brasile, 05652-900
        • Reclutamento
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasile, 01401-004
        • Reclutamento
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
    • British Columbia
      • Victoria, British Columbia, Canada, V8R 6V5
        • Reclutamento
        • Bc Cancer Victoria
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Reclutamento
        • Juravinski Cancer Centre
    • Quebec
      • Montreal, Quebec, Canada, QC H3t 1E2
        • Reclutamento
        • Jewish General Hospital
      • Montreal, Quebec, Canada, H4J 1C5
        • Reclutamento
        • Ciusss Nim Hscm
      • Québec, Quebec, Canada, G1J 1Z4
        • Reclutamento
        • Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Reclutamento
        • Ciusss de Lestrie Chus
      • Brno, Cechia, 625 00
        • Reclutamento
        • Fakultni Nemocnice Brno
      • Hradec Králové, Cechia, 500 03
        • Reclutamento
        • Fakultni Nemocnice Hradec Kralove
      • Olomouc, Cechia, 77900
        • Reclutamento
        • Fakultni Nemocnice Olomouc
      • Ostrava, Cechia, 708 00
        • Reclutamento
        • Fakultni Nemocnice Ostrava
      • PLZE, Cechia, 323 00
        • Reclutamento
        • Fakultni Nemocnice Plzen
      • Prague, Cechia, 10000
        • Reclutamento
        • Vseobecna Fakultni Nemocnice V Praze
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100730
        • Reclutamento
        • Peking Union Medical College Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Cina, 630014
        • Reclutamento
        • The First Affiliated Hospital of Chongqing Medical University
    • Fujian
      • Fuzhou, Fujian, Cina, 350005
        • Reclutamento
        • The First Affiliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510555
        • Reclutamento
        • Sun Yat Sen University Cancer Center Huangpu Branch
      • Guangzhou, Guangdong, Cina, 510000
        • Attivo, non reclutante
        • Zhujiang Hospital of Southern Medical University
    • Guangxi
      • Nanning, Guangxi, Cina, 530021
        • Reclutamento
        • The First Affiliated Hospital of Guangxi Medical University
    • Guizhou
      • Guiyang, Guizhou, Cina, 550002
        • Reclutamento
        • Guizhou Provincial Peoples Hospital
    • Heilongjiang
      • Harbin, Heilongjiang, Cina, 150000
        • Reclutamento
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, Cina, 450000
        • Reclutamento
        • Henan Cancer Hospital
    • Hunan
      • Changsha, Hunan, Cina, 410011
        • Reclutamento
        • The Second Xiangya Hospital of Central South University
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210029
        • Reclutamento
        • Jiangsu Province Hospital
      • Nantong, Jiangsu, Cina, 201203
        • Reclutamento
        • Affiliated Hospital of Nantong University
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330006
        • Reclutamento
        • The Second Affiliated Hospital of Nanchang University
    • Shaanxi
      • Xi'an, Shaanxi, Cina, 710004
        • Reclutamento
        • The Second Affiliated Hospital of Xian Jiaotong University
    • Shandong
      • Jinan, Shandong, Cina, 250000
        • Reclutamento
        • Shandong Provincial Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200025
        • Reclutamento
        • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    • Sichuan
      • Chengdu, Sichuan, Cina, 610071
        • Reclutamento
        • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 300020
        • Reclutamento
        • Institute of Hematology and Hospital of Blood Disease
    • Yunnan
      • Kunming, Yunnan, Cina, 650032
        • Reclutamento
        • First Affiliated Hospital of Kunming Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310002
        • Reclutamento
        • The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Corea del Sud, 13620
        • Reclutamento
        • Seoul National University Bundang Hospital
    • Seoul Teugbyeolsi
      • SeochoGu, Seoul Teugbyeolsi, Corea del Sud, 06591
        • Reclutamento
        • The Catholic University of Korea, Seoul St Marys Hospital
      • SeodaemunGu, Seoul Teugbyeolsi, Corea del Sud, 03722
        • Reclutamento
        • Severance Hospital Yonsei University Health System
      • Seoul, Seoul Teugbyeolsi, Corea del Sud, 03080
        • Reclutamento
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Corea del Sud, 05505
        • Reclutamento
        • Asan Medical Center
      • Bordeaux, Francia, 33076
        • Reclutamento
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • ClermontFerrand, Francia, 63100
        • Reclutamento
        • Chu Clermont Ferrand Therapie Cellulaire and Hematolo
      • Le Mans, Francia, 72037
        • Reclutamento
        • Centre Hospitalier Le Mans
      • Lille, Francia, 59000
        • Reclutamento
        • Hopital Claude Huriez Chu Lille
      • Lyon, Francia, 69373
        • Reclutamento
        • Centre Leon Berard
      • Montpellier, Francia, 34090
        • Reclutamento
        • Chu Montpellier Hopital Saint Eloi
      • Toulouse, Francia, 31100
        • Reclutamento
        • Iuc Toulouse Oncopole
      • Deggendorf, Germania, 94469
        • Reclutamento
        • Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
      • Frankfurt am Main, Germania, 60389
        • Reclutamento
        • Centrum Fur Haematologie Und Onkologie Bethanien
      • Münster, Germania, 48153
        • Reclutamento
        • Geho Munster
      • Straubing, Germania, 94315
        • Reclutamento
        • Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
      • Bologna, Italia, 40138
        • Reclutamento
        • Irccs Azienda Ospedaliero Universitaria Bologna
      • Florence, Italia, 50134
        • Reclutamento
        • Aou Careggi, Servizio Sanitario Toscana
      • Milan, Italia, 20132
        • Reclutamento
        • Ospedale San Raffaele
      • Milan, Italia, 20162
        • Reclutamento
        • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
      • Padova, Italia, 35128
        • Reclutamento
        • Azienda Ospedaliera Di Padova
      • Roma, Italia, 00168
        • Reclutamento
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Auckland, Nuova Zelanda, 1023
        • Reclutamento
        • Auckland City Hospital
      • Auckland, Nuova Zelanda, 0622
        • Reclutamento
        • North Shore Hospital
      • Christchurch, Nuova Zelanda, 8011
        • Reclutamento
        • Health New Zealand Canterbury
      • Dunedin, Nuova Zelanda, 9016
        • Reclutamento
        • Dunedin Hospital
      • Wellington, Nuova Zelanda, 6021
        • Reclutamento
        • Wellington Regional Hospital (Ccdhb)
      • Almere Stad, Olanda, 1315 RA
        • Reclutamento
        • Flevoziekenhuis
      • Dordrecht, Olanda, 3318 AT
        • Reclutamento
        • Albert Schweitzer Ziekenhuis
      • Sgravenhage, Olanda, 2545 AA
        • Reclutamento
        • Hagaziekenhuis
      • Brzozów, Polonia, 36-200
        • Reclutamento
        • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
      • Katowice, Polonia, 40-519
        • Reclutamento
        • Pratia Onkologia Katowice
      • Krakow, Polonia, 30-727
        • Reclutamento
        • Pratia McM Krakow
      • Lublin, Polonia, 20-090
        • Reclutamento
        • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
      • Wroclaw, Polonia, 50-367
        • Reclutamento
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Birmingham, Regno Unito, B15 2TH
        • Reclutamento
        • Queen Elizabeth Hospital
      • Bournemouth, Regno Unito, BH7 7DW
        • Reclutamento
        • University Hospitals Dorset Royal Bournemouth Hospital
      • Leeds, Regno Unito, LS9 7TF
        • Reclutamento
        • St Jamess University Hospital
      • London, Regno Unito, SE5 9RS
        • Reclutamento
        • Kings College Hospital
      • Norwich, Regno Unito, NR4 7UY
        • Reclutamento
        • Norfolk and Norwich University Hospitals Nhs Foundation Trust
      • Bucharest, Romania, 30171
        • Reclutamento
        • Coltea Clinical Hospital
      • Bucureti, Romania, 022328
        • Reclutamento
        • Institutul Clinic Fundeni
      • ClujNapoca, Romania, 400015
        • Reclutamento
        • Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
      • Granada, Spagna, 18014
        • Reclutamento
        • Hospital Universitario Virgen de Las Nieves
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre
      • Majadahonda, Spagna, 28222
        • Reclutamento
        • Hospital Universitario Puerta de Hierro Majadahonda
      • Murcia, Spagna, 30120
        • Reclutamento
        • Hospital Clinico Universitario Virgen de La Arrixaca
    • California
      • Duarte, California, Stati Uniti, 91010-3012
        • Reclutamento
        • City of Hope National Medical Center
      • Orange, California, Stati Uniti, 92868-3201
        • Reclutamento
        • Chao Family Comprehensive Cancer Center
      • Palo Alto, California, Stati Uniti, 94304-2205
        • Reclutamento
        • Stanford Cancer Institute
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80012-5405
        • Reclutamento
        • Rocky Mountain Cancer Centers (Williams) Usor
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32224-1865
        • Reclutamento
        • Mayo Clinic Jacksonville
      • Miami, Florida, Stati Uniti, 33140
        • Reclutamento
        • Mount Sinai Medical Center Braman Comprehensive Cancer Center
      • Tampa, Florida, Stati Uniti, 33612-9496
        • Reclutamento
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University
      • Zion, Illinois, Stati Uniti, 60099-2676
        • Reclutamento
        • Midwestern Regional Medical Center
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70121-2429
        • Reclutamento
        • Ochsner Clinic Foundation
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215-5418
        • Reclutamento
        • Dana Farber Cancer Institute
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905-0001
        • Reclutamento
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University of Nebraska Medical Center
    • New York
      • New York, New York, Stati Uniti, 10032
        • Reclutamento
        • Columbia University Medical Center
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204-2990
        • Reclutamento
        • Atrium Health Levine Cancer Institute (Lci)
      • Durham, North Carolina, Stati Uniti, 27705-3976
        • Reclutamento
        • Duke University Medical Center
    • Oregon
      • Eugene, Oregon, Stati Uniti, 97401
        • Reclutamento
        • Oncology Associates of Oregon Willamette Valley Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232-1309
        • Reclutamento
        • Upmc Hillman Cancer Center(Univ of Pittsburgh)
    • Texas
      • Tyler, Texas, Stati Uniti, 75702-7522
        • Reclutamento
        • Texas Oncology Tyler
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112-5550
        • Reclutamento
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, Stati Uniti, 98109-4433
        • Reclutamento
        • Fred Hutchinson Cancer Research Center
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226-3522
        • Reclutamento
        • Medical College of Wisconsin
      • Stockholm, Svezia, 171 76
        • Reclutamento
        • Karolinska Universitetssjukhuset Solna

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
  • Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
  • Measurable disease by Computer Tomography/Magnetic Resonance Imaging
  • Adequate bone marrow and organ function

Exclusion Criteria:

  • Previous systemic treatment for CLL
  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  • Known central nervous system involvement
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • Uncontrolled hypertension or clinically significant cardiovascular disease

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A: Sonrotoclax plus Zanubrutinib

Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation.

Administered orally.

Altri nomi:
  • BGB-11417

Administered orally.

Altri nomi:
  • Brukinsa
  • BGB-3111
Comparatore attivo: Arm B: Venetoclax plus Acalabrutinib

Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation.

Administered orally.

Altri nomi:
  • Calquenza

Administered orally.

Altri nomi:
  • Venclexta
  • Venclixto

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
Lasso di tempo: Up to approximately 70 months

PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

Up to approximately 70 months
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
Lasso di tempo: Up to approximately 16 months

Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS).

Up to approximately 16 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PFS in High-Risk Participants
Lasso di tempo: Up to approximately 70 months

PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

Up to approximately 70 months
Overall Survival (OS)
Lasso di tempo: Up to approximately 70 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 70 months
Overall Response Rate (ORR) as Determined by IRC
Lasso di tempo: Up to approximately 70 months

ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC.

Up to approximately 70 months
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
Lasso di tempo: Up to approximately 16 months

Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier).

Up to approximately 16 months
Number of Participants with Adverse Events
Lasso di tempo: Up to approximately 70 months

Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings.

Up to approximately 70 months
PFS Determined by Investigator Assessment
Lasso di tempo: Up to approximately 70 months

PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first.

Up to approximately 70 months
Complete Response Rate (CRR) by IRC and Investigator Assessment
Lasso di tempo: Up to approximately 70 months

CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier).

Up to approximately 70 months
ORR Determined by Investigator Assessment
Lasso di tempo: Up to approximately 70 months

ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator.

Up to approximately 70 months
Duration of Response (DOR)
Lasso di tempo: Up to approximately 70 months

Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders.

Up to approximately 70 months
Time to Next Treatment (TTNT)
Lasso di tempo: Up to approximately 70 months

TTNT is defined as the time from randomization to the start of the next treatment for CLL.

Up to approximately 70 months
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
Lasso di tempo: At baseline and up to approximately 70 months

Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life.

At baseline and up to approximately 70 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Study Director, BeOne Medicines

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 gennaio 2026

Completamento primario (Stimato)

1 febbraio 2031

Completamento dello studio (Stimato)

1 novembre 2031

Date di iscrizione allo studio

Primo inviato

2 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

2 dicembre 2025

Primo Inserito (Effettivo)

11 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • BGB-11417-304
  • 2025-524366-21-00 (Ctis)
  • 2025 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Periodo di condivisione IPD

See plan description

Criteri di accesso alla condivisione IPD

See plan description

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .